COMPANY

Exai Bio Inc.

HQ: Palo Alto, CA source · exai.bio ↗ · West Coast

Keywords: liquid biopsy oncology non-small cell lung cancer Exai oncRNA blood test

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $719K (SBIR Phase II 5R44CA291369-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA291369-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44CA291369-02
  Organization: EXAI BIO, INC.; City/State: PALO ALTO, CA; Project number: 5R44CA291369-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 718994; Administering IC: National Cancer Institute; Project title: Orphan Non-coding RNA-based Test for Detecting Minimal Residual Disease in Resectable Non-small Cell Lung Cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 14, 2023 Trial start —: Prospective Study of oncRNA Stratification of Cancer by Size and Stage source ↗

Jul 14, 2030 (ESTIMATED) · · Prospective Study of oncRNA Stratification of Cancer by Size and Stage · NCT05833360

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05833360	Prospective Study of oncRNA Stratification of Cancer by Size and Stage	Not listed	Recruiting	Jul 14, 2023	Jul 14, 2030 (estimated)

Annual award amounts. Total $2.0M.

Sep 17, 2026 NIH award 5R44CA291369-02 FY2026: $718,994 awarded for that fiscal year; activity R44 (SBIR); PI KU, JEREMY; recipient as written: EXAI BIO, INC., PALO ALTO, CA. Orphan Non-coding RNA-based Test for Detecting Minimal source ↗
Sep 12, 2024 NIH award 1R44CA291369-01A1 FY2024: $1,280,908 awarded for that fiscal year; activity R44 (SBIR); PI KU, JEREMY; recipient as written: EXAI BIO, INC., PALO ALTO, CA. Orphan Non-coding RNA-based Test for Detecting Min source ↗